Class IIa histone deacetylases (Class IIa HDACs) (Class IIa HDACs)

Class IIa histone deacetylases (HDACs) are a specific subgroup of the HDAC family, including HDAC4, HDAC5, HDAC7, and HDAC9, characterized by their unique ability to shuttle between the nucleus and cytoplasm in response to cellular signals (PubMed: 22564828). Unlike other HDAC classes, Class IIa enzymes exhibit minimal catalytic activity toward acetylated histones and primarily function as molecular scaffolds that recruit other corepressors, such as HDAC3 and SMRT/N-CoR, to regulate gene transcription (UniProt: P56524). They play pivotal roles in developmental processes, including myogenesis, bone formation, and the maintenance of neuronal identity (PubMed: 23911241). In disease states, Class IIa HDACs are frequently dysregulated; for instance, their nuclear exclusion is linked to cardiac hypertrophy, while their overexpression is observed in various malignancies and neurodegenerative conditions (PubMed: 28637762). Pharmacological targeting of Class IIa HDACs is an active area of research, with a focus on developing class-selective inhibitors to improve therapeutic efficacy and reduce the side effects associated with pan-HDAC inhibitors (PubMed: 30106574). These enzymes are also involved in metabolic regulation, influencing glucose homeostasis and lipid metabolism in tissues like the liver and skeletal muscle (PubMed: 21531337). Their interaction with transcription factors like MEF2 is a central mechanism by which they control tissue-specific gene expression programs (PubMed: 10622252).

Other names

HDAC4HDAC5HDAC7HDAC9Histone deacetylase 4Histone deacetylase 5Histone deacetylase 7Histone deacetylase 9Class IIa HDAC family

Class IIa HDAC inhibitors bind to the catalytic site of the enzymes, often chelating the zinc ion required for activity, or disrupt the recruitment of corepressor complexes, thereby preventing the deacetylation of histones and non-histone proteins and modulating gene expression (PubMed: 22564828, PubMed: 30106574).